PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has announced two critical presentations at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from May 13-17, 2025, in New Orleans, LA. These presentations will spotlight groundbreaking data from the company’s preclinical pipeline, advancing innovative approaches for autoimmune diseases and cancer treatment.
The first presentation, scheduled for May 13 from 6:00 p.m. to 7:30 p.m. CDT, will detail the use of a TGF-β neutralizing synthetic receptor designed to enhance solid tumor elimination under tumor microenvironment-mimicking conditions. The session will be led by Raisa Uchurova, Ph.D., Principal Scientist at Century Therapeutics (Abstract #1826, Poster #740).
On May 17 at 11:15 a.m. CDT, Century Therapeutics Associate Director Dar Heinze, M.D., will present preclinical findings on iPSC-derived CD19 CAR T cells. These findings demonstrate the ability of these cells to achieve tumor control and robust cell expansion comparable to healthy donor T cells. This oral abstract session highlights the significant therapeutic potential of precision-engineered cell therapies (Abstract #1857).
These presentations reflect Century Therapeutics’ dedication to advancing cell therapy as a meaningful solution to unmet medical needs. The company continues to push the boundaries of research in the effort to deliver next-generation treatments for patients with autoimmune diseases and cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.